Literature DB >> 17445681

Bladder cancer cell invasion is enhanced by cross-talk with fibroblasts through hepatocyte growth factor.

Pengfei Wang1, Masa-aki Nishitani, Shuji Tanimoto, Tomoteru Kishimoto, Tomoharu Fukumori, Masayuki Takahashi, Hiro-omi Kanayama.   

Abstract

OBJECTIVES: To examine the effects of fibroblast-derived humoral factors, especially hepatocyte growth factor (HGF), on the invasive potential of bladder cancer cells. Stromal cells in cancer tissue are thought to play an important role in the transformation and invasion of cancer cells.
METHODS: The influence of fibroblast cells (TIG-1 cells) and HGF on the invasive potential of bladder cancer cells (5637, T24, J82, HT1376, and MGHU-1 cells) was evaluated by in vitro cell invasion assay. The expression of HGF and c-Met, which is the receptor of HGF, was examined by reverse transcriptase-polymerase chain reaction. To clarify the relationship between the serum HGF level and invasive bladder cancer, we measured the serum concentrations of HGF in patients with bladder cancer without metastatic disease and normal controls, using an enzyme-linked immunosorbent assay.
RESULTS: The in vitro cell invasion assay showed that the number of invading bladder cancer cells was significantly increased by the conditioned medium (CM) of the fibroblast cells. HGF neutralization antibody partially inhibited the enhancement of invasiveness by fibroblast CM. The CM of fibroblasts cultured with bladder cancer CM stimulated cancer cell invasion more strongly (with increased HGF secretion) than did the CM of fibroblasts cultured without bladder cancer CM. The serum HGF levels were significantly greater in patients with muscle-invasive bladder cancer (regardless of tumor size) than in patients with non-muscle-invasive bladder cancer.
CONCLUSIONS: The present results have suggested that bladder cancer cell invasion is enhanced by cross-talk with fibroblasts through humoral factors, including HGF. Elucidation of this mechanism could lead to novel therapeutic strategies for bladder cancer.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17445681     DOI: 10.1016/j.urology.2007.01.063

Source DB:  PubMed          Journal:  Urology        ISSN: 0090-4295            Impact factor:   2.649


  14 in total

Review 1.  Targeted therapies in urothelial carcinoma.

Authors:  Monalisa Ghosh; Sam J Brancato; Piyush K Agarwal; Andrea B Apolo
Journal:  Curr Opin Oncol       Date:  2014-05       Impact factor: 3.645

2.  Priming cancer cells for drug resistance: role of the fibroblast niche.

Authors:  Wei Bin Fang; Min Yao; Nikki Cheng
Journal:  Front Biol (Beijing)       Date:  2014-02-01

Review 3.  [Tumour-stroma interactions in urothelial cancer].

Authors:  J Hatina; M Kripnerová; J Tuková; J Šrámek; P Dvořák; M Pešta; J Dobrá; V Babuška; J Racek; M Sobol; A Philimonenko; P Hozák; Z Czuba; W A Schulz; C Strell; S Grimm; S Jennek; K-H Friedrich
Journal:  Urologe A       Date:  2015-04       Impact factor: 0.639

Review 4.  The dynamic roles of the bladder tumour microenvironment.

Authors:  Yu-Cheng Lee; Hung-Ming Lam; Charles Rosser; Dan Theodorescu; William C Parks; Keith Syson Chan
Journal:  Nat Rev Urol       Date:  2022-06-28       Impact factor: 16.430

Review 5.  MET: a promising anticancer therapeutic target.

Authors:  Solange Peters; Alex A Adjei
Journal:  Nat Rev Clin Oncol       Date:  2012-05-08       Impact factor: 66.675

6.  Characterization of HGF/Met Signaling in Cell Lines Derived From Urothelial Carcinoma of the Bladder.

Authors:  Young H Lee; Andrea B Apolo; Piyush K Agarwal; Donald P Bottaro
Journal:  Cancers (Basel)       Date:  2014-11-25       Impact factor: 6.639

Review 7.  Met in urological cancers.

Authors:  Yasuyoshi Miyata; Akihiro Asai; Kensuke Mitsunari; Tomohiro Matsuo; Kojiro Ohba; Yasushi Mochizuki; Hideki Sakai
Journal:  Cancers (Basel)       Date:  2014-12-16       Impact factor: 6.639

8.  Identification of drugs as single agents or in combination to prevent carcinoma dissemination in a microfluidic 3D environment.

Authors:  Jing Bai; Ting-Yuan Tu; Choong Kim; Jean Paul Thiery; Roger D Kamm
Journal:  Oncotarget       Date:  2015-11-03

Review 9.  c-Met expression and activity in urogenital cancers - novel aspects of signal transduction and medical implications.

Authors:  Ralf Hass; Susanne Jennek; Yuanyuan Yang; Karlheinz Friedrich
Journal:  Cell Commun Signal       Date:  2017-02-17       Impact factor: 5.712

Review 10.  Understanding and Targeting MET Signaling in Solid Tumors - Are We There Yet?

Authors:  Witthawat Ariyawutyakorn; Siriwimon Saichaemchan; Marileila Varella-Garcia
Journal:  J Cancer       Date:  2016-03-20       Impact factor: 4.207

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.